MetaCap

Hemab Therapeutics Holdings Inc. (COAG)

NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.29-0.57 (-1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

COAG stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.55
52-week range
23.00 – 55.42
Day range
38.77 – 40.19
Volume / Avg
347.01K / 495.96K
Beta
—

52-week range

$23.00$55.42

COAG stock today

Shares of Hemab Therapeutics (COAG) finished lower on Nov 20 at $39.29, a drop of 1.43% or $0.57 per share, versus the S&P 500's 3.70% decline. At this level, COAG sits in the middle of its 52-week range of $23.00 to $55.42: 29.1% below the high, set on Aug 14, 2026 and 70.8% above the low. Hemab Therapeutics has posted a net loss over the last twelve months (EPS of -$3.55), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Hemab Therapeutics

Company profile

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Benny Sorensen M.D., Ph.D.
Headquarters
Cambridge, MA
Employees
59
IPO year
2026
Website
hemab.com

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$63.00+60.35%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $54.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.58 vs $-0.51
Surprise
-13.73%

COAG news

All COAG news

Hemab Therapeutics peers

Health Care sector
COAG peer companies
CompanyPrice% ChgMarket capCompare
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs COAG
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs COAG
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs COAG
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs COAG
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs COAG
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs COAG
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs COAG
ALVOAlvotech4.12-3.96%$1.47Bvs COAG

Indexes, lists and sector

Hemab Therapeutics stock FAQ

What is Hemab Therapeutics's stock price today?

COAG last traded at $39.29 as of Nov 20, 4:00 PM EST, down 1.43% on the day. Prices are delayed at least 15 minutes.

Who is Hemab Therapeutics's CEO?

Dr. Benny Sorensen M.D., Ph.D. is the chief executive officer of Hemab Therapeutics Holdings Inc., which has about 59 employees.

What is the COAG 52-week high?

The 52-week high for COAG is $55.42 and the 52-week low is $23.00. The stock is currently 29.1% below its high.

Compare COAG